GlaxoSmithKline — the drug giant working with Impax Laboratories Inc. on a late-stage Parkinson’s disease drug — has filed a patent infringement suit against Impax around a generic version of its male health drug Jalyn.
It is at least the fourth such suit filed against Hayward-based Impax (NASDAQ: IPXL) in little more than five months because Impax regularly challenges the validity of patents while it seeks to be the first on the market with generic versions of those drugs.
No comments:
Post a Comment